Ticker

Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced the issuance of two new U.S. patents and the allowance of an additional U.S. patent application covering its proprietary IL-4 and IL-13 Superkine platforms, including…

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses  Up to 80 patients with locally advanced melanoma will be randomized in this Investigator-sponsored, multicenter Phase 1b NEO-CYT trial led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G.